8 stories mentioning ERASUpdated 14d ago
Every FINWIRES story that references ERAS, newest first.
Erasca (ERAS) shares rose 1.5% in Thursday afternoon trading after BofA Securities upgraded the stock to neutral from underperform and raised its price target to $16 from $9.Trading volume stood at over 5.5 million shares, compared with a daily average of about 6.9 million shares.Price: $13.38, Change: $+0.20, Percent Change: +1.52%
Erasca's (ERAS) early pan-RAS data have shifted the focus from whether ERAS-0015 is active to its potential commercial impact, with recent clinical results and stronger key opinion leader feedback strengthening confidence in the program's activity profile, BofA Securities said in a Thursday note.The analyst said ERAS-0015 has shown clinically meaningful activity across non-small cell lung cancer, pancreatic, and colorectal cancers, supporting Erasca's position in the competitive RAS-targeted therapy space, with safety appearing manageable so far but longer follow-up needed to confirm durability and survival benefit.BofA highlighted ERAS-4001 as a key pipeline opportunity in the second half of 2026 if it shows a broader therapeutic window and improved tolerability, while also citing colorectal cancer combinations and upcoming clinical readouts as near-term catalysts for sentiment and valuation.The outlook is now more balanced after early data, with upside from further efficacy confirmation, combinations, and readouts, while risks include durability, safety, competition, and uncertainty around differentiation and market path, the report added.BofA raised its rating on the stock to neutral from underperform and increased its price target to $16 from $9.Shares of Erasca were up 2.9% in Thursday trading.Price: $13.49, Change: $+0.31, Percent Change: +2.35%
Erasca (ERAS) has an average rating of buy and mean price target of $20.91, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Healthcare stocks were lower late Monday afternoon, with the NYSE Healthcare Index down 0.3% and the State Street Healthcare Select Sector SPDR ETF (XLV) declining 0.4%.The iShares Biotechnology ETF (IBB) was little changed.In corporate news, Zoetis (ZTS) shares fell 7.5% after BNP Paribas cut its price target to $146 from $185, following the company's Q1 results late last week.Moderna (MRNA) has been working on early-stage vaccines targeting hantaviruses, Bloomberg reported Friday, citing a company statement. The research began before recent infections were reported aboard the Dutch-flagged Hondius, the report said. Moderna shares fell 3.7%.Sonida Senior Living (SNDA) shares fell 3.3% after the company reported Q1 loss of $2.39 per diluted share, widening from the loss of $0.77 a year earlier. Analysts polled by FactSet expected a loss of $1.53.Erasca (ERAS) entered into a clinical trial collaboration and supply agreement with Merck (MRK) to study its investigational drug ERAS-0015 in combination with Keytruda in patients with RAS-mutant solid tumors. Erasca shares rose 3%.
Healthcare stocks were mixed Monday afternoon with the NYSE Healthcare Index rising 0.2% and the State Street Healthcare Select Sector SPDR ETF (XLV) little changed, paring earlier losses.The iShares Biotechnology ETF (IBB) increased 0.3%.In corporate news, Moderna (MRNA) has been working on early-stage vaccines targeting hantaviruses, Bloomberg reported Friday, citing a company statement. The research began before recent infections were reported aboard the Dutch-flagged Hondius, the report said. Moderna shares fell 2.2%.Sonida Senior Living (SNDA) shares fell 3.6% after the company reported Q1 loss of $2.39 per diluted share, widening from the loss of $0.77 a year earlier. Three analysts polled by FactSet expected a loss of $1.53.Erasca (ERAS) entered a clinical trial collaboration and supply agreement with Merck (MRK) to study its investigational drug ERAS-0015 in combination with Keytruda in patients with RAS-mutant solid tumors. Erasca shares rose 3.3%, and Merck added 1.2%.
Erasca (ERAS) shares fell 48% Tuesday after the company reported preliminary phase 1 dose-escalation data for its experimental ERAS-0015 in patients with RAS-mutant solid tumors, including colorectal cancer, non-small-cell lung cancer and pancreatic adenocarcinoma.The preliminary data, from ongoing trials in the US and China, suggest ERAS-0015 may be combined with standard-of-care doses of panitumumab, positioning it as a potential backbone therapy for future combination regimens, the company said.The therapy was generally "well tolerated," with no dose-limiting toxicities or treatment discontinuations due to adverse events, according to a statement.Erasca said it selected 24 mg and 32 mg once daily as recommended doses for further study and said the drug showed "promising clinical potential" for combination use with panitumumab.In a regulatory filing, the company said a patient, who was a 66 year-old male with heavily pretreated metastatic pancreatic adenocarcinoma, had died. The company said grade 3 treatment-related adverse events of pneumonitis progressed to grade 5 following withdrawal of supportive care per patient decision.Price: $9.96, Change: $-9.20, Percent Change: -48.02%
Erasca (ERAS) shares were down 48% in Tuesday premarket activity, continuing Monday's loss.Greenland Energy (GLND) stock was 37% lower after the company said late Monday it priced a $70 million offering of 17.5 million shares at $4 apiece.High-Trend International (HTCO) shares were down 24%, shaving gains from the previous session.Rambus (RMBS) shares were 18% lower after Baird downgraded the company to neutral from outperform.NOV (NOV) stock was down 2% after the company posted overnight lower Q1 net income and revenue.
Erasca (ERAS) said in a filing Tuesday that it has narrowed the timeline for the data readout of its phase 1 trials evaluating its pan-RAS molecular glue ERAS-0015 to not later than mid-May, compared with prior guidance of H1.The company is evaluating ERAS-0015 in a phase 1 trial in patients with RAS-mutant solid tumors, while its licensor Guangzhou Joyo Pharmatech is evaluating ERAS-0015 in patients with advanced solid tumors harboring specific RAS mutations in China, according to a filing with the US Securities and Exchange Commission.Shares of Erasca were up 3.9% in Tuesday trading.Price: $22.55, Change: $+0.84, Percent Change: +3.87%
